Drug Trial Radar · NCT07241936
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
444
Planned (sponsor's estimate)
Start
Nov 13, 2025
Primary completion
Oct 30, 2027
Study completion Oct 30, 2028
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study adopts a multi-center, open-label, non-randomized trial design. It plans to enroll patients with Advanced solid tumor. Dose-escalation and PK-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with Different ADCs (DP303c/SYS6043/SYS6002/SYS6010) in this patient population, and to confirm the recommended phase 2 dose (RP2D).
Conditions
- Advanced Solid Tumors
Interventions
sirolimus (albumin-bound)Drug
intravenous infusion
DP303cDrug
intravenous infusion
SYS6043Drug
intravenous infusion
SYS6002Drug
intravenous infusion
SYS6010Drug
intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The occurrence and frequency of adverse events (AE) and serious adverse events (SAE)Time frame: Up to approximately 36 weeks after the first participant is enrolled
- dose - limiting toxicities (DLT)Time frame: Up to approximately 36 weeks after the first participant is enrolled
- The recommended phase 2 doseTime frame: Up to approximately 36 weeks after the first participant is enrolled
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.